Introduction {#Sec1}
============

Among the various molecular chaperone families, the DNAJ family is the largest and most heterogeneous group, named after their common nominator, the J domain, which is responsible for the interactions with the ATP-dependent Hsp70 (HSPA) refolding machinery. Canonically, the DNAJ proteins bind to substrate proteins, transport, and present them to Hsp70 for refolding. The J domain also stimulates the ATPase activity of Hsp70. The DNAJ family members are thought to be responsible for substrate specificity (Kampinga and Craig [@CR24]). Molecular chaperones in the protein quality control system assist folding and degradation of substrate proteins (Tyedmers et al. [@CR48]) and suppress aggregation and cytotoxicity induced by heat shock or other proteotoxic insults (Kampinga [@CR23]; Morimoto [@CR34]).

Neurodegenerative polyglutamine diseases are caused by a CAG triplet expansion in the affected gene, which leads to an aggregation-prone prolonged polyglutamine (polyQ) stretch in the encoded protein (Gatchel and Zoghbi [@CR14]). Stretches with polyQ occur in many human proteins, e.g., in transcription factors. This suggests that such polyQ stretches have an evolutionary early and important cellular function (Ramazzotti et al. [@CR39]; Schaefer et al. [@CR44]). The normal form of the human huntingtin (Htt) protein contains a polyQ stretch of 11 to 34 glutamines in exon 1 (HttEx1). An expansion of the number of glutamines to above 35 leads to Huntington's disease (HD), a severe disease hallmarked by protein fibrillation and neuronal inclusion body formation, linked to a progressive neurodegenerative process with uncontrolled movements, personality changes, and cognitive impairment. The length of the polyQ stretch is statistically related to the age of onset of HD: the longer, the earlier the onset of symptoms (Novak and Tabrizi [@CR36]). Fibrillation propensity is also dependent on polyQ length as shown in several cell and animal models as well as in vitro data with purified proteins (de Almeida et al. [@CR11]; Kar et al. [@CR25]). All these suggest that aggregation initiates disease, although the nature of the toxic entities (fibrils or precursor oligomeric forms) that cause neurodegeneration is subject to debate.

Various molecular chaperones have been studied for their involvement in polyQ diseases (Gestwicki and Garza [@CR15]). Within the DNAJ protein family, the HSJ1a (DNAJB2a) (Labbadia et al. [@CR27]) and DNAJB1 (Lotz et al. [@CR31]) have been reported to suppress polyQ aggregation in cooperation with the Hsp70 machinery. However, in a cell-based screen of various molecular chaperones from the HSPH, HSPA, and DNAJ families, the most effective to suppress polyQ aggregation are two closely related DNAJ homologues, DNAJB6 and DNAJB8 (Hageman et al. [@CR18]). Suppression had previously been observed for DNAJB6 in a human cell line (Chuang et al. [@CR9]) and for the *Drosophila* ortholog Mrj-1 (Fayazi et al. [@CR13]). Interestingly, the suppression of polyQ aggregation by DNAJB6 (Hageman et al. [@CR18]) was found to be independent of the Hsp70 machinery. In fact, the N-terminal J domain, required for Hsp70 interactions, was largely dispensable for this effect.

The mechanism of polyQ fibrillation and the influence of the polyQ context within proteins are not fully understood at the molecular level (Bieschke et al. [@CR5]; Wetzel [@CR51]). Aggregation in nine different polyQ diseases (HD, x-linked spinal and bulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and six forms of spinocerebellar ataxia) is tightly associated with polyQ stretches in nine functionally and structurally unrelated proteins (Zoghbi and Orr [@CR53]). Furthermore, polyQ stretches fused to green fluorescent protein (GFP) affect, for example, motility in *Caenohabditis elegans* models (Morley et al. [@CR35]), and polyQ stretches alone cause toxicity in *Drosophila* (Marsh et al. [@CR32]). Thus, it appears that it is the polyQ stretches that drive aggregation.

Several reports suggest that aggregation initiation is associated with processing of polyQ-containing proteins by proteases, since the full-length polyQ-containing proteins are less prone to aggregation (Harris et al. [@CR19]; Ratovitski et al. [@CR41]). The context around the polyQ stretch does seem, however, important, probably, both for its processing into such smaller fragments (Wellington et al. [@CR50]; Berke et al. [@CR2]; Jung et al. [@CR22]; Graham et al. [@CR17]) as well as for the (co)aggregation proneness of the generated fragments (Dehay and Bertolotti [@CR12]). The proteasome is unable to cleave expanded polyQ stretches (Holmberg et al. [@CR20]; Venkatraman et al. [@CR49]). Proteasomal processing of polyQ-containing proteins or fragments generated thereof may therefore yield highly aggregation-prone polyQ peptides (Raspe et al. [@CR40]), not readily digested by peptidases (Menzies et al. [@CR33]). These polyQ peptides could thus be a major initiator of aggregation and disease, by seeding the aggregation of polyQ-containing proteins. Recently, cellular polyQ aggregation, initiated by overexpression of peptides with expanded polyQ stretches, was found to be efficiently suppressed by co-expression of DNAJB6 and DNAJB8 (Gillis et al. [@CR16]). Such suppression could be due to either an indirect effect on other cellular components or to a direct interaction between DNAJB6/DNAJB8 and polyQ peptides.

In order to obtain further evidence for a direct interaction between DNAJB6 and polyQ and to gain insight into the suppression mechanism, we decided to purify the proteins, focusing on the functional characterization of DNAJB6 since it is ubiquitously expressed, including in the brain, whereas DNAJB8 is only expressed in the testis (Hageman et al. [@CR18]). We decided to evaluate the suppression by thioflavin T binding, which is among the most widely used tools in the study of amyloid fibrils (Biancalana and Koide [@CR4]; Wu et al. [@CR52]), using purified polyQ peptides as well as purified polyQ constructs within a HttEx1 context. We found that the purified DNAJB6 protein formed large heterogeneous oligomers, consistent with the oligomeric state found in human cell lines, and that DNAJB6 efficiently suppressed the fibrillation of polyQ peptides under conditions where DNAJB1 and the Hsp70 machinery had no effect.

Materials and methods {#Sec2}
=====================

Recombinant expression and purification of DNAJB6/8 {#Sec3}
---------------------------------------------------

The human DNAJB6b and DNAJB8, cloned and sequenced as previously described (Hageman et al. [@CR18]), were subcloned into pET/TOPO-151 vector (Invitrogen, Paisley, UK) containing a hexa His-tag, a V5-tag, and a tobacco etch virus (TEV) protease cleavage site. The plasmids were transformed into *Escherichia coli* strain ER2566 and grown in LB medium with 50 mg/l ampicillin. Overnight cultures of 5 ml were used to inoculate 500 ml cultures in 2.5-l baffled flasks in a shaker at 37 °C. Isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside was added at OD~600~ = 1, and cells were collected 3--4 h later by centrifugation at 6,000×*g* for 5 min and frozen at −20 °C. Cell pellets were dissolved in buffer (20 mM sodium phosphate buffer, pH 8.0, 150 mM NaCl, 5 mM dithiothreitol (DTT)), with DNAse (Sigma-Aldrich, Stockholm, Sweden) and protease inhibitor (cOmplete EDTA free; Roche Diagnostics Scandinavia AB, Stockholm, Sweden) added just prior to cell lysis, which was performed by passing twice through a French press, followed by centrifugation at 20,000×*g*. The supernatant was discarded, the pellet was washed in the same buffer including 0.75 % Tween-20, centrifugation was repeated, and pellet was finally resuspended in the same buffer without Tween-20, but with 8 M urea, which was, thereafter, aliquoted and stored at −20 °C. For affinity chromatography, the sample was thawed and diluted tenfold in the same buffer with no urea, and imidazole was added to a final concentration of 20 mM. The sample was loaded on the HisTrap column (GE Healthcare Lifesciences, Uppsala, Sweden), washed with buffer containing 20 mM imidazole, and eluted with buffer containing 350 mM imidazole. The His-tag was cleaved with TEV protease (Invitrogen, Paisley, UK) at a protein concentration of 1 mg/ml and 1 unit protease per 3 μg protein at 20 °C overnight. After cleavage, the sample was diluted with imidazole-free buffer and concentrated using the Centriprep centrifugal filter devices (Millipore AB Sweden, Solna, Sweden) and applied a second time to the HisTrap column. The flow-through was collected and contained the His-tag-free proteins, whereas the cleaved off His-tag, any remaining uncleaved His-tagged protein, and the TEV protease, which contains a non-cleavable His-tag, were retained on the column. Protein concentration was determined using the Bradford assay (Bradford [@CR6]; Stoscheck [@CR45]) with bovine serum albumin (BSA) as standard. Non-denaturing (native polyacrylamide gel electrophoresis (PAGE)) and sodium dodecyl sulfate (SDS)-PAGE was performed using precast 3--12 % NativePAGE Bis-Tris Gels and precast 4--12 % NuPAGE® SDS-PAGE Bis-Tris Gels (Life Technologies Europe BV, Stockholm, Sweden), stained with colloidal Coomassie Brilliant Blue (Lawrence and Besir [@CR28]) and scanned with the Image Scanner III using the software Labscan/IQTL (GE Healthcare Lifesciences, Uppsala, Sweden).

Dynamic light scattering {#Sec4}
------------------------

Dynamic light scattering (DLS) measurement was used to assess particle size using the Zetasizer Nano S (Malvern Instruments, Malvern, UK) amenable for measurements on particles between 0.3 nm to 10 μm.

Size exclusion chromatography {#Sec5}
-----------------------------

Size exclusion chromatography (SEC) was performed by gel filtration using the HiPrep Sephacryl S-400 16/60 column (GE Healthcare Lifesciences, Uppsala, Sweden). The column was equilibrated with buffer (20 mM sodium phosphate buffer, pH 8.0, 150 mM NaCl) and operated at a flow rate of 0.5 ml/min at 4 °C. Fractions of 0.5 ml were collected and protein elution followed by detection of the absorbance at 280 nm.

Expression and purification of maltose-binding protein-fused HttEx1 and polyQ peptide {#Sec6}
-------------------------------------------------------------------------------------

Recombinant C-terminally hexa His-tagged maltose-binding protein (MBP)-TEV-HttEx1Qn and N-terminally hexa His-tagged MBP-TEV-Qn of varying lengths (*n* = 15 and 45) were expressed in *E. coli* strain BL21(DE3) (Stratagene, Santa Clara, CA, USA) and purified in three steps. The proteins were first eluted from the 10-ml bed volume Talon metal affinity resin column (Clontech, Saint-Germain-en-Laye, France), equilibrated in 20 mM Tris--HCl, pH 7.5; 100 mM KCl; 20 mM imidazole; 10 % glycerol; and 1 mM DTT by developing an imidazole gradient (20--500 mM). The His-tagged MBP-TEV-HttEx1Qn and the MBP-TEV-Qn of varying lengths were eluted from this column in 200 mM imidazole. The fractions containing His-tagged MBP-TEV-HttEx1Qn were pooled and loaded on the UnoQ6 column (BioRad, Marnes-la-Coquette, France) equilibrated in 20 mM Tris--HCl, pH 7.5; 20 mM KCl; and 1 mM DTT. The column was washed with five bed volumes of the equilibration buffer, and the fusion proteins were eluted using a KCl gradient (20--500 mM). His-tagged MBP-TEV-HttEx1Qn eluted from this column at 200 mM KCl, and their concentrations were determined from their absorbance at 280 nm using an extinction coefficient of 67840 M^−1^ cm^−1^.

Removal of MBP from HttEx1 {#Sec7}
--------------------------

MBP-TEV protease, produced using the plasmid pRK1043 (Addgene, Cambridge, MA, USA), was added to the eluted protein at a 1:5 *w*/*w* ratio and 100 % cleavage, as assessed using SDS-PAGE, and was achieved upon incubating the mixture for 1 h at 37 °C. The mixture was then loaded on the 1-ml bed volume Talon column, the column was washed with 20 bed volumes of 20 mM Tris--HCl, pH 7.5, and 100 mM KCl, and HttEx1Qn was eluted in 20 mM Tris--HCl, pH 7.5; 100 mM KCl; and 200 mM imidazole. The protein was immediately desalted using PD-10 desalting columns (GE Healthcare, Uppsala, Sweden) equilibrated in 50 mM HEPES--KOH, pH 7.5, and 150 mM NaCl; aliquoted; flash frozen in liquid nitrogen; and stored at −80 °C until use. The protein concentrations in the final eluate were systematically comparable to that following cleavage as assessed by SDS-PAGE analysis.

Removal of MBP from polyQ peptide {#Sec8}
---------------------------------

The fractions containing hexa His-tagged MBP-TEV-Qn (1.5 mg/ml) were incubated with His-tagged TEV (0.3 mg/ml) (Invitrogen, Paisley, UK) for 20 min at room temperature. The mixture was then diluted tenfold and loaded on the 5-ml bed volume HiTrap Q FF column (GE Healthcare, Uppsala, Sweden). The column was washed with ten bed volumes of 20 mM HEPES, pH 7.5, and Qn peptides was eluted in 20 mM HEPES, pH 7.5, and 300 mM NaCl. His-tagged MBP and TEV were trapped in-line on the 10-ml Talon column. The Qn peptides were immediately aliquoted, flash frozen in liquid nitrogen, and stored at −80 °C until use.

Electron microscopy {#Sec9}
-------------------

The DNAJB6 protein was applied to glow discharged carbon-coated grids and stained with 1 % uranyl acetate for negative stain electron microscopy (EM). Images were recorded, using a JEOL JEM2100F microscope at 200 kV and a magnification of 40,000 times, equipped with the Tietz 4k × 4k CCD camera (Tietz Video and Image Processing Systems GmbH, Gauting, Germany). HttEx1Qn and Qn assemblies were observed by TEM in the JEOL 1400 transmission electron microscope following adsorption onto carbon-coated 200-mesh grids and negative staining with 1 % uranyl acetate. The images were recorded with the Gatan Orius CCD camera (Gatan, München, Germany).

Fibrillation assay based on thioflavin T fluorescence increase {#Sec10}
--------------------------------------------------------------

The constructs of purified His-tagged MBP-TEV-HttEx1Qn and MBP-TEV-Qn of varying lengths were used to monitor fibril formation by continuous measurement of thioflavin T (ThT) fluorescence increase (Linse et al. [@CR30]). The final volume was 100 μl per well in a 96-well, low-binding, half-area microplate (Corning 3881; Corning Incorporated Life Sciences, Acton, MA) kept on ice, while constructs from 30 μM stock solutions were mixed to a final concentration of 15 μM (or as else stated) with filtered and degassed buffer (Tris--HCl, pH 7.4 and 150 mM KCl); the final concentration of ThT was 10 μM, and the final concentration of DNAJB6, DNAJB8, and DNAJB1 (obtained from Sigma-Aldrich, Stockholm, Sweden) was varied as stated in figure legends. All molar ratios between proteins are calculated on a monomer-to-monomer basis, although the same oligomeric DNAJB6 protein was used in all assays. HSPA1 (Sigma-Aldrich, Stockholm, Sweden) was added in a molar ration to DNAJB of 2:1, together with 2 mM ATP and 5 mM MgCl~2~. After adding TEV protease (molar ratio protein to protease 50:1), the microplate plate was sealed with a plastic film to avoid evaporation and immediately inserted into the plate reader FLUOstar Omega (BMG Labtech, Offenburg, Germany) and incubated at 37 °C without agitation. ThT fluorescence was recorded every 150 s through the bottom of the plate with excitation and emission filters of 440 and 480 nm, respectively. Fibrillation under seeded conditions was performed by adding preformed fibrils, from a fibrillation assay experiment on the previous day, corresponding to an additional 5 or 20 % of the monomer concentration (10 μM).

Fibrillar assembly monitored as formation of SDS-insoluble material {#Sec11}
-------------------------------------------------------------------

The assembly of purified HttEx1Qn and Qn peptides into fibrils was monitored also by SDS-PAGE as disappearance of the band corresponding to monomeric, SDS-soluble HttEx1Q45 and Q45 and concomitant appearance of SDS-insoluble material accumulated at the top of the gel using 13 % Tris--tricine (Q45) or 12 % Tris--glycine (HttEx1Q45) gels stained with SYPRO Orange (Invitrogen, Paisley, UK) followed by imaging with a LAS-3000 (Fujifilm, Tokyo, Japan) using the software Multigauge (Life Science Systems), for quantification of protein bands. Experiments were performed two to six times, and the data presented are representative of the experiments we performed.

Secondary structure prediction of DNAJB6 and sequence alignment {#Sec12}
---------------------------------------------------------------

The sequences of human DNAJB6 (isoform B, sp\|O75190-2) and DNAJB8 (sp\|Q8NHS0), three ortogues to each of them, and human DNAJB1 (sp\|P25685) were subjected to secondary structure prediction using several different programs (JPRED, APSSP, NetSurfP, PROF, SCRATCH, JUFO, PSIPRED, YASPIN, PORTER, and PROTPRED) at ExPASy website ([http://www.expasy.org](http://www.expasy.org/)) and compared to the secondary structure determined for human DNAJB1, the N-terminal domain (PDB 1HDJ; Qian et al. [@CR38]), and the C-terminal domain (PDB 3AGX; Suzuki et al. [@CR47]). Sequence alignment was performed with Clustal Omega ([www.ebi.ac.uk/Tools/msa/clustalo](http://www.ebi.ac.uk/Tools/msa/clustalo)).

Results {#Sec13}
=======

DNAJB6 is an oligomeric protein {#Sec14}
-------------------------------

The DNAJB6 was recombinantly expressed in *E. coli* and purified by affinity chromatography (Fig. S[1](#MOESM1){ref-type="media"}, Table S[1](#MOESM1){ref-type="media"}). The His-tag was removed by cleavage with TEV protease, and when occasionally, the cleavage was incomplete; not only His-tagged DNAJB6 but also untagged DNAJB6 was retained on the column. This suggested that the purified DNAJB6 protein is not in a monomeric form, in consistence with the findings that in cells, DNAJB6 (Sarparanta et al. [@CR43]) as DNAJB8 (Hageman et al. [@CR18]) forms large oligomers. The oligomeric state of DNAJB6 was further analyzed by DLS (Fig. [1a](#Fig1){ref-type="fig"}), SEC (Fig. [1b](#Fig1){ref-type="fig"}), native PAGE (Fig. [1c](#Fig1){ref-type="fig"}), and negative stain EM (Fig. [1d](#Fig1){ref-type="fig"}), altogether revealing a polydisperse population of particles, with an average radius size of 12.7 nm (Table [1](#Tab1){ref-type="table"}). The size distribution of the oligomers was similar for DLS measurements at temperatures from 10 to 40 °C and at concentrations ranging from 0.03 to 3 mg/ml (data not shown). Attempts to fractionate the heterogeneous DNAJB6 oligomers by SEC resulted in subpopulations of different size, as seen with native PAGE (Fig. [1c](#Fig1){ref-type="fig"}) and DLS (Table [1](#Tab1){ref-type="table"}), which, however, still were heterogeneous. So, unlike what is known for most other DNAJB proteins that, generally, are thought to form dimers (Kampinga and Craig [@CR24]; Cheetham and Caplan [@CR8]; Li et al. [@CR29]), DNAJB6 forms large and polydisperse oligomers.Fig. 1DNAJB6 forms large heterogeneous oligomers. Purified DNAJB6 protein was analyzed by DLS (**a**) and SEC (**b**), with molecular weight marker in *gray dashed line*. Fractions of the oligomeric DNAJB6 peak, of which three are marked *3*, *6*, and *9*, were further analyzed with native PAGE (**c**) where *MW* molecular standard, *lane 1* unfractionated sample, and *lanes 2--10* SEC fractions. The fractions marked with an *asterisk* were also analyzed with DLS (Table [1](#Tab1){ref-type="table"}), and fraction *6* was stained with uranyl acetate for negative stain EM (**d**) with a *scale bar* corresponding to 100 nmTable 1Size determination of DNAJB6 oligomers by DLSSEC fractionRadius sizeSDMWSD(nm)(kDa)Unfractionated12.74.71,280478313.23.31,400352610.82.8880231910.42.5810196Values are presented from DLS measurements of DNAJB6 oligomers, without (unfractionated) and with (fractionated: 3, 6, and 9) prior fractionation by SEC (Fig. [1b](#Fig1){ref-type="fig"}). Same fractions were also analyzed by native PAGE (Fig. [1c](#Fig1){ref-type="fig"})

Assessment of PolyQ fibrillation {#Sec15}
--------------------------------

The high propensity of polyQ to form β-sheet-rich fibrils is documented by different experimental techniques, including CD, EM, and X-ray diffraction (Papaleo and Invernizzi [@CR37]). That fibrils bind the fluorescent dye ThT (Krebs et al. [@CR26]) is underlying one of the most widely used tools in the study of amyloid fibrils (Biancalana and Koide [@CR4]; Wu et al. [@CR52]). We evaluated the effect of DNAJB6 on fibrillation, with polyQ as a peptide (Qn) and in the context of HttEx1 (HttEx1Qn), with *Q* = 15 or 45. The sequences were GAMKSF(Q)nF and GAMATLEKLMKAFESLKSF(Q)nPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPGSLHHHHHH (with residues in HttEx1 underlined), resulting in molecular mass 6.5 and 14 kDa, respectively, for *n* = 45. Since the constructs are highly prone to aggregation, they were expressed and purified as fusions with MBP (Fig. S[2](#MOESM1){ref-type="media"}). Fibrillation was initiated by addition of TEV protease, which starts the release of the fibrillation-prone polyQ monomers from MBP, and was monitored by continuous measurement of ThT fluorescence. For both Q45 (Fig. [2a](#Fig2){ref-type="fig"}) and HttEx1Q45 (Fig. [2b](#Fig2){ref-type="fig"}), fibrillation occurred in a concentration-dependent manner, as previously reported (Wetzel [@CR51]). To yield information on the dominating fibrillation pathway (Cohen et al. [@CR10]), half times of fibrillation were extracted (Table [2](#Tab2){ref-type="table"}) from the curves in Fig. [2a, b](#Fig2){ref-type="fig"}. A power function was fitted to *t*~0.5~ versus concentration *c* (*t*~0.5~ = *C* × *c*^*k*^), where *C* is a constant, and *k* is the slope in the log--log plot (Fig. [2c](#Fig2){ref-type="fig"}). Assuming a dimer as critical nucleus, these *k* values for Q45 and HttEx1Q45 (−1.2 and −1.3, respectively) suggest that the fibrillation was largely dependent on the so-called primary nucleation (Cohen et al. [@CR10]). No increase in ThT fluorescence was observed neither for Q15 nor HttEx1Q15 (data not shown). In agreement with this, no fibrils were observed by for Q15 nor HttEx1Q15 (Fig. [2d, f](#Fig2){ref-type="fig"}), whereas the increase in ThT fluorescence intensity recorded both for Q45 and HttEx1Q45 correlated with the appearance of fibrils (Fig. [2e, g](#Fig2){ref-type="fig"}).Fig. 2Concentration-dependent polyQ fibrillation. Fibrillation was measured as the ThT fluorescence increase, and triplicate samples are shown for Q45 peptide (**a**) and for HttEx1Q45 (**b**), at protein concentrations 6.4, 8, 10, 12.8, 16, and 20 μM, color coded with increasingly *darker blue* indicating increasing concentration. The difference in absolute fluorescence intensity between Q45 and HttEx1Q45 is arbitrary and gives no quantitative comparison of their extent of fibrillation. Half times of fibrillation (*t* ~0.5~ values, Table [2](#Tab2){ref-type="table"}) were extracted from the curves in **a** and **b** and log *t* ~0.5~ plotted against the log concentration of Q45 peptide and HttEx1Q45, respectively (**c**). Samples of polyQ peptide (**d**, **e**) and HttEx1 (**f**, **g**) with Q15 (**d**, **f**) or Q45 (**e**, **g**) were visualized with TEM to confirm fibril formation. *Scale bars* correspond to 200 nmTable 2Concentration-dependent PolyQ fibrillationConcentrationQ45HttEx1Q45(μM)*t* ~0.5~ (h)SD*t* ~0.5~ (h)SD6.416.00.28.90.3811.60.26.30.0109.20.14.40.112.87.20.33.30.1165.30.02.60.1204.10.12.20.0Fibrillation was measured as ThT fluorescence increase at various concentrations of polyQ. The half time (*t* ~0.5~) for fibrillation was extracted from the curves in Fig. [2a](#Fig2){ref-type="fig"} (Q45) and Fig. [2b](#Fig2){ref-type="fig"} (HttEx1Q45), respectively, and plotted in Fig. [2c](#Fig2){ref-type="fig"}

### Suppression of polyQ fibrillation by DNAJB6 {#d30e1110}

Having established a robust fibrillation assay for Q45 and HttEx1Q45, we next assessed the effect of DNAJB6 on fibrillation. The lag phase preceding fibrillation increased with increasing concentrations of DNAJB6 (Fig. [3](#Fig3){ref-type="fig"}). For Q45 (Fig. [3a](#Fig3){ref-type="fig"}), fibrillation suppression occurred at a molar ratio polyQ to DNAJB6 as low as 1:0.01. For HttEx1Q45, the fibrillation suppression was less efficient (Fig. [3b](#Fig3){ref-type="fig"}). Suppression can be estimated as the increase in the *t*~0.5~ values for fibrillation and was increased by DNAJB6 approximately tenfold for Q45 at a 1:0.1 M ratio, but only by a factor of 3 for HttExQ45 at a similar molar ratio. At lower molar ratio (1:0.01), the *t*~0.5~ of fibrillation was increased by a factor of 2 for Q45, while no significant effects were seen for HttEx1Q45.Fig. 3Suppression of fibrillation of Q45 and HttEx1Q45 by DNAJB6. Fibrillation was measured in triplicates as the relative ThT fluorescence increase, at 15 μM Q45 (**a**) or HttEx1Q45 (**b**) with DNAJB6 added in varying polyQ to DNAJB6 molar ratios: 1:0.1 (*red*), 1:0.01 (*dark pink*), 1:0.001 (*pink*), no added DNAJB6 (*black*), and BSA added in ratio 1:0.1 (*yellow green*). Note the difference in time scale between Q45 and HttEx1Q45. Molar ratios were calculated as monomer to monomer, although DNAJB6 is oligomeric

### Suppression of polyQ fibrillation by DNAJB6 in presence of preformed fibrils {#d30e1166}

To investigate the mechanism of fibrillation suppression further, we performed experiments under seeded conditions to mimic later stages where some nuclei have been formed already, and elongation of fibrils and secondary nucleation processes may occur (Cohen et al. [@CR10]). Fibrillation suppression by added DNAJB6 was evaluated without seeding (primary nucleation dominates) and by seeding with preformed fibrils at two concentrations (5 %, secondary nucleation may dominate, and 20 %, the elongation of fibrils dominates), for Q45 (Fig. [4a](#Fig4){ref-type="fig"}) and HttEx1Q45 (Fig. [4b](#Fig4){ref-type="fig"}). The suppression was largest under non-seeded conditions, but not insignificant under seeded conditions. Thus, there is clearly an effect of DNAJB6 not only on the primary nucleation but also on later stages of fibrillation.Fig. 4Suppression of fibrillation of Q45 and HttEx1Q45 by DNAJB6 in the presence of preformed fibrils. Fibrillation was measured as the relative ThT fluorescence increase at 10 μM Q45 (**a**) or HttEx1Q45 (**b**) under different seeding conditions: no seed (*black*) without and with DNAJB6 (*red*), seeding with 5 % preformed fibrils (*dark blue*) without and with DNAJB6 (*purple*), seeding with 20 % preformed fibrils (*light blue*) without and with DNAJB6 (*pink*), with preformed fibrils taken after 20 h of incubation according to Fig. [3](#Fig3){ref-type="fig"}. The molar ratio between chaperone and polyQ was 1:0.01 for Q45 and 1:0.1 for HttEx1. Molar ratios were calculated as monomer to monomer, although DNAJB6 is oligomeric

### Suppression of the formation of SDS-insoluble aggregates by DNAJB6 {#d30e1217}

As a complement to the evaluation of polyQ aggregation as the formation of fibrils by ThT fluorescence measurements, we also followed the polyQ aggregation by continuous withdrawal of samples for SDS-PAGE and assessment of the distribution of protein between bands representing the monomeric forms of Q45 and HttEx1Q45, respectively (Fig. [5a, c](#Fig5){ref-type="fig"}) and bands representing SDS-insoluble aggregates at the top of the gel (Fig. [5b, d](#Fig5){ref-type="fig"}). Quantification of the band intensities after imaging showed disappearance of monomeric forms (Fig. [5e, f](#Fig5){ref-type="fig"}) and concomitant appearance of SDS-insoluble aggregates (Fig. [5g, h](#Fig5){ref-type="fig"}), in approximately 24 h for Q45 and 1 h for HttEx1Q45. Thus, for Q45, the formation of ThT-binding fibrils (Fig. [3a](#Fig3){ref-type="fig"}) preceded the formation of SDS-insoluble aggregates (Fig. [5c](#Fig5){ref-type="fig"}), whereas for HttEx1Q45, the formation of ThT-binding fibrils (Fig. [3b](#Fig3){ref-type="fig"}) and aggregates (Fig. [5d](#Fig5){ref-type="fig"}) occurred rather simultaneously and more rapidly than for Q45. This is consistent with previous observations of peptides relative to the exon 1 of huntingtin, where the N-terminal 17 amino acids cause an initial aggregation prior to rearrangement and fibril formation (Papaleo and Invernizzi [@CR37]). Equimolar amounts of DNAJB6 fully prevented aggregation of Q45 during 84 h (Fig. [5a, c](#Fig5){ref-type="fig"}), and delayed it fourfold for HttEx1Q45 (Fig. [5b, d](#Fig5){ref-type="fig"}). With substoichiometric amounts of DNAJB6 (1:0.1), the monomeric form of Q45 and HttEx1Q45 disappeared, and the same amount of SDS-insoluble aggregates appeared in case of HttEx1Q45, but not for Q45 (Fig. [5d](#Fig5){ref-type="fig"}, compared to c). Hence, even substoichiometric amounts of DNAJB6 interact with Q45 monomers and counteract the appearance of insoluble aggregates.Fig. 5Suppression of the formation of SDS-insoluble aggregates by DNAJB6. Formation of SDS-insoluble polyQ aggregates was followed on SDS-PAGE for 20 μM Q45 (**a**, **c**) and Ex1Q45 (**b**, **d**) in the absence (**a**, **b**) or presence (**c**, **d**) of 20 μM DNAJB6. Gels were stained for 1 h (**b**, **d**) or 3 h (**a**, **c**) with SYPRO Orange. This dye is poorly bound to HttEx1Q45 and even more so to Q45, which appear as faintly stained bands on the gels, despite being present at much higher levels than DNAJB6. Protein band intensities were quantified and plotted as a relative amount of soluble monomers (**e**, **f**) or SDS-insoluble aggregates (**g**, **h**) at 20 μM Q45 (**e**, **g**) and HttEx1Q45 (**f**, **h**) without DNAJB6 (*filled circles*) or with DNAJB6 in a molar ratio of 1:0.1 (*open diamonds*) or 1:1 (*filled squares*). Molar ratios were calculated as monomer to monomer, although DNAJB6 is oligomeric. Note the difference in time scale between Q45 and HttEx1Q45. The data were fitted to the sigmoidal equation *y* = *a*/(1 + exp(*b*(*c* − *x*))), where *a* is the proportion of aggregates at steady state, *b* is the slope of the exponential growth phase, and *c* is the time where 50 % of the aggregation is reached

### Fibrillation suppression by DNAJB6 compared to other DNAJB proteins {#d30e1367}

To evaluate how specific the polyQ fibrillation suppression by DNAJB6 is compared to other DNAJB proteins, we added DNAJB6, its close homologue DNAJB8, and the more canonical family member, the structurally characterized homologue DNAJB1. DNAJB6 suppressed fibrillation of Q45 entirely, DNAJB8 delayed fibrillation by a factor of 4, and DNAJB1 delayed fibrillation only slightly, at a molar ratio 1:0.1 (Fig. [6a](#Fig6){ref-type="fig"}). At a molar ratio 1:0.01 where DNAJB1 had no effect at all, DNAJB6 still delayed fibrillation with nearly a factor 3 (data not shown). For HttExQ45, the fibrillation was delayed 2.5-fold with DNAJB6 and, to a small extent, by DNAJB1 and DNAJB8 (Fig. [6b](#Fig6){ref-type="fig"}). The suppression of polyQ fibrillation by DNAJB6 was not further enhanced in presence of HSPA1 and ATP (Fig. [7](#Fig7){ref-type="fig"}), confirming the finding in cellular systems that suppression of polyQ aggregation by DNAJB6 is HSPA1/ATP independent (Hageman et al. [@CR18]; Gillis et al. [@CR16]). Thus, DNAJB6 has unique fibrillation suppression properties, which are lacking in DNAJB1 and, probably, are located in the C-terminal and putatively substrate-binding domain which is not very conserved among the many different DNAJB proteins. The sequence similarity between DNAJB6 and DNAJB1 is largest in the N-terminal J domain (59 % sequence identity) and in the C-terminal domain that has been structurally characterized for DNAJB1, showing two β-sandwich folds each with 2 + 3 antiparallel β-strands and one α-helix and α-helical dimerization domain (Suzuki et al. [@CR47]; Hu et al. [@CR21]), and the sequence identity is too low (17 %) for homology modeling. However, secondary structure predictions and sequence alignment (Fig. S[3](#MOESM1){ref-type="media"}), with the structure determined for DNAJB1 correlating well with the prediction for DNAJB1, suggest that DNAJB6 and DNAJB8 have one β-sandwich fold in the C-terminal domain (Fig. [8](#Fig8){ref-type="fig"}).Fig. 6Specificity in suppression of fibrillation by DNAJB6. Fibrillation was measured as the relative ThT fluorescence increase, and incubation was made at 15 μM Q45 (**a**) and HttEx1Q45 (**b**) with no chaperone (*black*), DNAJB6 (*red*), DNAJB8 (*green*), and DNAJB1 (*blue*). The monomeric molar ratio between chaperone and polyQ was 1:0.1. Molar ratios were calculated as monomer to monomer, although DNAJB6 is oligomericFig. 7Suppression of fibrillation by DNAJB6 with and without HSPA1. Fibrillation was measured as the relative ThT fluorescence increase, and incubation was made of 15 μM Q45 (**a**, **b**) and HttEx1Q45 (**c**, **d**) with no chaperone in the absence (*black*) or presence (*gray*) of HSPA1, with DNAJB6 in the absence (*red*) or presence (*pink*) of HSPA1, and with DNAJB1 in the absence (*dark blue*) or presence (*light blue*) of HSPA1. The monomeric molar ratio between chaperone and polyQ was 1:0.01. Molar ratios were calculated as monomer to monomer, although DNAJB6 is oligomericFig. 8Secondary structure prediction to assess the C-terminal domain of DNAJB6. Secondary structure prediction, with predicted α-helices in *red*, predicted β-strands in *yellow* for human DNAJB6b (isoform B, sp\|O75190-2), its closest paralogue DNAJB8 (sp\|Q8NHS0), and its more distantly related paralogue, DNAJB1 (sp\|P25685) for which the structure has been determined to atomic resolution \[PDB:1HDJ for the N-terminal domain (Qian et al. [@CR38]), PDB:3AGX for the C-terminal domain (Suzuki et al. [@CR47])\], with α-helices as *red* and β-strands as *yellow boxes* below the aligned sequences

Discussion {#Sec17}
==========

Here, we have shown that the purified DNAJB6 protein forms heterogeneous oligomers that cannot be separated into more homogeneous fractions (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). This resembles the polydisperse and dynamic oligomerization of some small heat shock proteins for example αB-crystallin (Baldwin et al. [@CR1]). DNAJB6 efficiently suppressed fibrillation of Q45 and, less efficiently, suppressed fibrillation of HttEx1Q45 (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, and [5](#Fig5){ref-type="fig"}). Furthermore, DNAJB6 was undoubtedly more efficient in suppressing fibrillation than DNAJB1 and independent on the presence of HSPA1 and ATP (Figs. [6](#Fig6){ref-type="fig"} and [8](#Fig8){ref-type="fig"}). These data obtained with purified proteins provide evidence in support of the effects previously observed in cells, when overexpression of DNAJB6 was combined with expression of GFP-labeled huntingtin exon 1 (Hageman et al. [@CR18]) and polyQ peptides (Gillis et al. [@CR16]).

DNAJB6 was identified, together with its closest homologue DNAJB8, as unique polyQ aggregation suppressors among the human HSPA, HSPH, and DNAJ family members (Hageman et al. [@CR18]). The suppression was largely independent of the expression of Hsp70 members. The absence of a comparable polyQ aggregation inhibitory effect of DNAJB1 that shares a homologous J domain but has little sequence resemblance with DNAJB6 in its C-terminus (only 17 %) supports the crucial role for the C-terminal domain of DNAJB6 and DNAJB8 in the polyQ aggregation suppression. The DNAJB1 C-terminus lacks a serine-rich motif (SSF-SST) and two lysines that were found to be important for the anti-aggregation function (Hageman et al. [@CR18]) (Fig. [8](#Fig8){ref-type="fig"}).

DNAJB6 was more efficient in suppressing fibrillation of polyQ peptides than HttEx1 with polyQ stretches of identical length, as assessed by ThT fluorescence (Fig. [3](#Fig3){ref-type="fig"}) and the formation of SDS-insoluble aggregates (Fig. [5](#Fig5){ref-type="fig"}). There may be several reasons for this. The fibrillation-promoting properties of the polyQ-flanking regions within HttEx1 might counteract DNAJB6-mediated inhibition, or these regions might disfavor the interaction between DNAJB6 and polyQ. The polyQ context, specifically the 17 N-terminal amino acids in HttEx1, significantly increases polyQ fibrillation propensity (Wetzel [@CR51]); (Papaleo and Invernizzi [@CR37]), which could make it more difficult to counteract fibrillation. The inhibition of polyQ aggregation by DNAJB6 anyway appears to be largely context independent with the polyQ stretch as the only common denominator, since DNAJB6 was also very efficient at suppressing aggregation of other polyQ-containing proteins, like ataxin-3 and the androgen receptor (Hageman et al. [@CR18]).

So, how can our current findings of highly efficient suppression of polyQ peptide aggregation by DNAJB6 be related to its anti-aggregation and toxicity-preventing effects in cellular (Hageman et al. [@CR18]; Chuang et al. [@CR9]) and animal models (Hageman et al. [@CR18]; Fayazi et al. [@CR13]) of polyQ diseases? One obvious possibility relates to the findings that proteins containing expanded polyQ stretches are not fully degraded by the proteasome (Venkatraman et al. [@CR49]). As a consequence, polyQ peptides that have a high propensity to aggregate into fibrillar assemblies (Wetzel [@CR51]) are released from the proteasome during the degradation of huntingtin (Holmberg et al. [@CR20]; Venkatraman et al. [@CR49]) and other polyQ proteins. That free polyQ peptides are not readily detected in cells can be due to their immediate capture by DNAJB6-like chaperones and subsequent degradation by peptidases or autophagy (Menzies et al. [@CR33]). If such processing fails, polyQ peptides would, however, become enriched and immediately seed aggregation into both main and side chain hydrogen-bonded fibrillar structures (Berryman et al. [@CR3]; Streets et al. [@CR46]). Other proteins containing Q stretches or protease-generated fragments of the polyQ proteins next will co-aggregate with such peptides and contribute to the toxicity by either direct aggregated toxicity or (secondary) loss of function of these sequestered proteins. The rate and propensity of this will likely depend on the context around the polyQ stretches in these fragments (Dehay and Bertolotti [@CR12]). If released in the cellular environment upon cell death, aggregates can be transmitted to neighboring cells and act as seeds promoting the aggregation of endogenous polyQ-containing proteins (Ren et al. [@CR42]), reminiscent of the spreading seen for the prion PrP (Brundin et al. [@CR7]). To mimic proteasomal release of polyQ peptides in living cells, overexpression of genetically engineered constructs of polyQ peptides was therefore performed, showing that the polyQ peptides induced the formation of aggregates in which polyQ-containing proteins and other heat shock proteins (HSPs) were detected, supporting the view that polyQ peptides can act as seeds for aggregation (Raspe et al. [@CR40]).

Moreover, using the same cell system, it was recently shown that co-expression of these genetically engineered constructs of polyQ peptides with DNAJB6 suppressed aggregation (Gillis et al. [@CR16]). Interestingly, in the few aggregates that did form, DNAJB6 and DNAJB8 were found in the core of the aggregates, whereas other chaperones (HSPA1) only associated with the periphery of the aggregates. This is indicating that DNAJB6 interacts early and directly with polyQ peptides as shown in this study, and the other HSPs interact later and more indirectly, presumably not until after the aggregates have formed.

To summarize, the data presented in this study show that DNAJB6 can directly bind to and highly efficiently suppress polyQ peptide fibrillation initiated by soluble, pure polyQ peptides. This is in line with recent cellular findings that DNAJB6 is a very strong protector against protein toxicity associated with polyQ aggregation diseases. The view of DNAJB6 as a peptide-binding chaperone that can sweep up polyQ peptides that are incompletely degraded by and released from the proteasome and suppress fibrillation initiation makes DNAJB6 an interesting target for therapy against such protein aggregation diseases.
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